Notícias Alnylam Pharmaceuticals Inc - ALNY | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Alnylam Pharmaceuticals Inc (ALNY)
Alnylam Pharmaceuticals Inc (ALNY) Notícias

Alnylam Pharmaceuticals Inc (ALNY)

244,89

-1,91

(-0,77%)

Fechado 24 Novembro 6:00PM

Atrasado por 15 minutos

244,40

-0,49

(-0,20%)

Após o horário de negociação: 9:27PM

Atrasado por 15 minutos

Discussões em tempo real e ideias de negociação: Negocie com confiança com nossa poderosa plataforma.

Alnylam to Webcast TTR Investor Day

Alnylam présente les résultats détaillés de l'étude de phase 3 HELIOS-B positive de Vutrisiran▼ chez les patients atteints d'amylose ATTR avec cardiomyopathie au congrès de la Société européenne de cardiologie

Alnylam präsentiert detaillierte Ergebnisse der positiven HELIOS-B-Phase-3-Studie mit Vutrisiran▼ bei Patienten mit ATTR-Amyloidose mit Kardiomyopathie auf dem Kongress der Europäischen Gesellschaft für Kardiologie

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Europäischer Kardiologenkongress 2024: Alnylam legt detaillierte Ergebnisse der Phase-3-Studie HELIOS-B zu Vutrisiran▼ bei ATTR-Amyloidose mit Kardiomyopathie vor

Alnylam présentera des résultats détaillés de l'étude HELIOS-B de phase 3 pour le vutrisiran▼ chez les patients atteints d'amylose ATTR avec cardiomyopathie lors du congrès 2024 de la Société européenne de cardiologie

Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

1
2
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Alnylam Pharmaceuticals

FTSE 350 Technology

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições